Artal Group S.A. Uni Qure N.V. Transaction History

Artal Group S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$29.24 - $42.03 $20.5 Million - $29.4 Million	-700,000 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$35.35 - $50.67 $1.77 Million - $2.53 Million	-50,000 Reduced 6.67%	700,000 $25.3 Million
Q3 2020 Nov 13, 2020	SELL	$35.98 - $47.66 $9 Million - $11.9 Million	-250,000 Reduced 25.0%	750,000 $27.6 Million
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $6.76 Million - $10.2 Million	-150,000 Reduced 13.04%	1,000,000 $45.1 Million
Q1 2020 May 14, 2020	BUY	$40.01 - $73.97 $46 Million - $85.1 Million	1,150,000 New	1,150,000 $54.6 Million

148

34.1M

1.07M

603K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $187M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.